In this article, we will take a look at some of the most affordable biotech stocks that are currently offering attractive upside potential.
On July 6, BioPharma Dive reported that drug developers producing new medicines for the treatment of autoimmune disorders and cancer accounted for more than 40% of venture financing rounds in the first six months of 2026. During the first half, 26 prominent investors injected approximately $9 billion into venture-funded biotech companies. Of this amount, a little over $3.9 billion was invested in cancer and immune drugmakers.
PitchBook’s Senior Analyst, Ben Zercher, said that while areas such as cardiometabolic disorders and obesity might witness some exits, venture funding is expected to persist across immunology and cancer segments as these areas are not highly time-sensitive.
Zercher highlighted that private immune drugmakers are also gaining a lot of attention, as companies like RayThera, Ouro Medicines, and Candid Therapeutics have been receiving a significant amount of funding. Speaking of potential strategic M&A deals within this space, he stated:
“If your T-cell engager can go between oncology and immunology, that looks really attractive to big pharma right now. I could see M&A activity coming just from a pipeline optionality standpoint as we approach the patent cliff.”
With that background, let’s explore our 10 Affordable Biotech Stocks to Buy Right Now.
everything possible/Shutterstock.com
Our Methodology
To identify relevant stocks for this article, we screened U.S.-listed biotech companies with market capitalizations above $2 billion and a forward P/E ratio below 10. Also, we only shortlisted stocks with at least 30% upside potential, according to consensus, as of the July 10 close. Finally, we selected 10 stocks with the highest upside and ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Cogent Biosciences Inc. (NASDAQ:COGT)
Cogent Biosciences Inc. (NASDAQ:COGT) is one of the 10 affordable biotech stocks to buy right now.
On June 30, Cogent Bioscience Inc. (NASDAQ:COGT) disclosed that it filed a New Drug Application for bezuclastinib, a drug for the treatment of Advanced Systemic Mastocytosis. The application to the U.S. FDA is backed by encouraging clinical results from the APEX key trial.
Cogent’s President and Chief Executive Officer, Andrew Robbins, stated that they are currently engaging closely with the FDA on each of its three submissions. He remains optimistic that bezuclastinib will attain its initial approvals by the end of 2026. He also acknowledged the efforts of the company’s development team, stating:
“I’d also like to congratulate our small, but exceptionally talented, Cogent development team, whose amazing work analyzing, presenting and submitting data from three pivotal trials in less than twelve months has rapidly positioned the company to achieve our vision of creating best-in-class therapies for patients fighting rare, mutational driven diseases.”
Back in mid-June, the company revealed preclinical findings for its innovative JAK2 V617F mutation-specific inhibitor at the European Hematology Association Congress 2026. Robbins stated that this selective inhibitor has the ability to target the underlying mutational cause of a disease while also reducing the off-target blood-related impacts. He added that they are currently expediting the program and also plan to file the Investigational New Drug application in 2026.
Cogent Biosciences Inc. (NASDAQ:COGT) is a clinical-stage biotechnology company that develops precision therapeutics for genetically defined illnesses. The company’s lead therapeutic candidate, bezuclastinib, is a selective tyrosine kinase inhibitor nearing a Phase 3 trial. It is designed to target KIT receptor mutations involved in systemic mastocytosis and advanced gastrointestinal stromal tumors.
9. Tango Therapeutics Inc. (NASDAQ:TNGX)
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 affordable biotech stocks to buy right now.
On June 29, Canaccord Genuity increased its target price on Tango Therapeutics Inc. (NASDAQ:TNGX) from $42 to $46, resulting in more than 53% upside potential. The firm kept a Buy rating on the stock, highlighting further upside from vopimetostat + KRAS inhibitors in NSCLC.
The price target adjustment is based on a revised valuation model that incorporates combined revenues from the therapy.
Earlier on June 26, Jefferies upgraded Tango Therapeutics Inc. (NASDAQ:TNGX) from Hold to Buy. The firm also increased its target price substantially from $27 to $60, leading to an upside of more than 100% at the prevailing level.
Despite a 242% rally so far during 2026, Jefferies anticipates further upside following promising data for vopimetostat plus daraxonrasib. It highlighted that this represents a plausible opportunity worth more than $4 billion, covering around 25%-40% of patients with pancreatic ductal adenocarcinoma.
During the second week of June, the company signed an underwriting agreement with Leerink Partners and J.P. Morgan Securities for an offering involving almost 18.2 million of the company’s common stock, as well as pre-funded warrants for more than 1.83 million shares.
The common stock offering was priced at $30 per share, while the warrants were priced at $29.99. The company expects to realize net proceeds of around $566.5 million, which will be used to fund pivotal trials, R&D spending, corporate needs, and commercial efforts.
Tango Therapeutics Inc. (NASDAQ:TNGX) is a precision oncology company focusing on the discovery and development of drugs targeting defined patient populations with unaddressed clinical needs. It develops TNG462, TNG45, and PRMT5 inhibitors for the treatment of pancreatic, lung, and brain cancer, respectively. The company is currently engaged in the development of TNG260 to treat lung cancer.
8. Beam Therapeutics Inc. (NASDAQ:BEAM)
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now.
On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a favorable resolution announced by Prime Medicine regarding its arbitration with Beam.
Stranahan forecasted a target price of $47, which yields more than 33% upside potential at the current level. He highlighted that although the resolution went in Prime’s favor, it will not have much of an impact on Beam. This is because it is only applicable to Prime’s PM647 rather than its entire editing estate.
For Beam, Stranahan noted that based on impressive data for the BEAM-302 biomarker, the focus now will be entirely on the execution of its alpha-1 antitrypsin deficiency. Currently, he sees Prime as a “distant threat” to the company.
Back on June 18, Beam Therapeutics Inc. (NASDAQ:BEAM) disclosed that the U.S. FDA has approved the filing of an investigational new drug, relating to BEAM-304 for phenylketonuria therapy. The company remains focused on BEAM-304 using a novel development strategy in which several mutation-based editors are designed as part of a unified clinical program.
Beam’s President, Giuseppe Ciaramella, Ph.D., stated that the FDA approval facilitates Beam’s approach of designing several mutation-targeted base editors via a unified clinical platform initiative. She also stated that the company plans to launch its Phase 1/2 trial.
Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that develops precision genetic medicines and also engages in gene therapies and genome editing research. Since its launch, the company has been spearheading CRISPR-based editing that facilitates the development of advanced genetic medicines.
7. Palvella Therapeutics Inc. (NASDAQ:PVLA)
Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the 10 affordable biotech stocks to buy right now.
On June 29, Palvella Therapeutics Inc. (NASDAQ:PVLA) disclosed that it filed the initial module of its New Drug Application with the FDA for approval of QTORIN 3.9% rapamycin anhydrous gel. QTORIN is used to treat microcystic lymphatic malformations.
The company plans to file the remaining modules and conclude the NDA application process during the latter half of 2026. The company highlighted that QTORIN rapamycin has attained FDA designations for Orphan Drug, Fast Track designations, and Breakthrough Therapy. The company is also speeding up U.S. launch preparation for a possible independent commercial launch in the early half of 2027, subject to approval.
Earlier on June 22, the company revealed that the FDA had provided a rolling review for QTORIN rapamycin’s New Drug Application. Palvella Founder and CEO, Wes Kaupinen, highlighted that the company plans to use the Breakthrough Therapy, the benefits of rolling review, and Fast Track designations to facilitate an efficient route toward achieving FDA approval. He further stated:
“Following the positive Phase 3 SELVA results, our focus is clear: move with urgency to advance QTORIN rapamycin as the potential first FDA-approved therapy for patients and families affected by microcystic LMs, a serious, lifelong rare disease with no approved treatment options.”
Palvella Therapeutics Inc. (NASDAQ:PVLA) is engaged in the development and marketing of innovative medical technologies and treatments for people suffering from severe and uncommon genetic skin diseases. QTORIN rapamycin, which is the company’s leading product, is currently undergoing Phase 3 trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations.
6. Dyne Therapeutics Inc. (NASDAQ:DYN)
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 affordable biotech stocks to buy right now.
On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock. The firm stated that the company’s Force platform has the potential to improve drug delivery in neuromuscular and CNS diseases by overcoming the related limitations.
Further, TD Cowen stressed the fact that the company’s late-stage candidates offer the potential to become top-notch therapies. These include z-basivarsen, which targets myotonic dystrophy type 1, and z-rostudirsen, which is used for exon 51 Duchenne muscular dystrophy mutations.
On June 17, Dyne Therapeutics Inc. (NASDAQ:DYN) finalized amendments to its non-dilutive senior secured term loan arrangement with Hercules Capital. As part of the revised arrangement, $50 million had already been funded at the closing of this amendment. In addition to that, Dyne has the option to draw $50 million in term loan tranche, depending on some milestones that need to be achieved.
There were amendments made to the final term loan facility as well, which involved expanding the tranche by $25 million. This means that Dyne has access to $125 million in capital, at Hercules’ discretion.
Dyne Therapeutics Inc. (NASDAQ:DYN) is a biotechnology company that formulates life-transforming targeted therapeutics for individuals with genetically driven neuromuscular diseases. It makes use of its FORCE platform to identify the root cause of a condition and currently has a strong pipeline of clinical and preclinical programs.
While we acknowledge the potential of DYN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DYN and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Affordable Biotech Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
